Financial Performance - The group recorded revenue of approximately HKD 710,873,000 for the six months ended June 30, 2022, a decrease from HKD 721,974,000 in the same period of 2021[5]. - The group reported a loss of approximately HKD 6,824,000 for the six months ended June 30, 2022, compared to a profit of HKD 24,675,000 in the same period of 2021[5]. - The fair value gain on investment properties decreased to approximately HKD 886,000, down from HKD 49,175,000 in the previous year[9]. - The share of losses from associates amounted to approximately HKD 11,243,000, a shift from a profit of HKD 14,165,000 in the same period of 2021[10]. - Revenue for the six months ended June 30, 2022, was HKD 710,873,000, a decrease of 1.53% from HKD 721,974,000 in the same period of 2021[83]. - Gross profit for the same period was HKD 188,082,000, down 21.97% from HKD 241,036,000 year-on-year[83]. - Basic and diluted loss per share was HKD 0.34, compared to earnings of HKD 0.07 per share in the prior year[84]. - The company reported a loss before tax of HKD 25,763,000 for the first half of 2022, compared to a profit of HKD 51,319,000 in the same period of 2021[130]. - The company’s total comprehensive income for the six months ended June 30, 2022, was HKD 3,855,035,000, a decrease from HKD 4,154,633,000 in the previous year[98]. Revenue Sources - The group's Hong Kong medical network management business generated revenue of approximately HKD 201.97 million, representing about 28.41% of total revenue for the first half of 2022[17]. - Revenue from general, specialist, and dental medical services was approximately HKD 270,217,000, representing about 38.01% of total revenue, an increase from 29.65% in 2021[20]. - Revenue from Hong Kong medical services was HKD 270,217,000, an increase from HKD 214,056,000 in the previous year, representing a growth of about 26.2%[116]. - Revenue from mainland China hospital management and medical services was HKD 233,613,000, up from HKD 217,097,000, indicating an increase of approximately 7.6%[116]. Operational Impact of COVID-19 - The significant decline in revenue was primarily attributed to a decrease in COVID-19 testing services[8]. - The fifth wave of the pandemic and government-imposed social distancing measures severely impacted consumer activity and the economic atmosphere in Hong Kong[11]. - The group continued to provide reputable healthcare services while supporting government vaccination and testing efforts during the pandemic[11]. - The group administered over 1.3 million vaccine doses in Hong Kong, accounting for approximately 7.4% of the total doses administered in the region as of June 30, 2022[12]. - The health management business in Shandong, Guangdong, and Shenzhen was impacted by varying degrees of pandemic control measures, but the management team focused on developing specialized services and expanding quality customer base[25]. Strategic Initiatives and Acquisitions - The company has agreed to acquire Central Medical for a total consideration of HKD 476,000,000, which includes HKD 356,000,000 in convertible bonds and HKD 120,000,000 in cash[50]. - The acquisition of Central Medical was completed on August 26, 2022, with a cash payment of HKD 120 million and the issuance of convertible bonds[53]. - The company plans to invest and develop multiple specialized medical centers in Hong Kong and a dental clinic chain in China by the end of 2023, with a total investment of HKD 150 million[55]. - The company aims to develop a dental chain and invest in medical clinics and hospitals in China, with a total investment of HKD 1,500 million planned by the end of 2023[59]. - The company is focusing on market expansion through strategic partnerships and acquisitions in the healthcare sector[172]. Financial Position and Assets - The group's current assets and total assets as of June 30, 2022, were approximately HKD 1,897,001,000 and HKD 4,139,977,000, respectively[5]. - As of June 30, 2022, the group's bank balance and cash amounted to approximately HKD 1,419,887,000, an increase from HKD 910,458,000 as of December 31, 2021[39]. - The group’s equity attributable to the owners was approximately HKD 3,773,354,000 as of June 30, 2022, down from HKD 3,855,035,000 as of December 31, 2021[41]. - The company’s total equity as of June 30, 2022, was HKD 4,139,977,000, down from HKD 4,225,434,000 at the end of 2021[94]. - The company’s total receivables, including other receivables and prepayments, amounted to HKD 448,936,000 as of June 30, 2022, compared to HKD 442,581,000 as of December 31, 2021[150]. Legal and Compliance Matters - The company has initiated legal proceedings in response to claims made by Profit Castle and Dr. Ye, seeking damages and other remedies[46]. - The company continues to seek legal advice regarding the Joyous Convertible Notes and related litigation matters[44]. - The company has not received any acceptable repayment proposals from Dr. Ye and Profit Castle, leading to unsuccessful negotiations regarding the overdue bill[147]. - The company has initiated legal action against Dr. Ye and Profit Castle for the recovery of the overdue bill and accrued interest[148]. - The company’s legal claims against Mr. Dai are still pending, with an appeal filed by Mr. Dai against a previous judgment[145]. Governance and Management - The company maintained compliance with the corporate governance code as of June 30, 2022, ensuring transparency and accountability to shareholders and creditors[73]. - The company appointed six new executive directors and two independent non-executive directors on June 28, 2022, increasing the total board members to eight executive directors, two non-executive directors, and four independent non-executive directors[74][77]. - The company’s audit committee reviewed the accounting principles and practices adopted by the group, ensuring alignment with financial reporting standards[77]. - The company confirmed that all directors complied with the securities trading code during the reporting period, maintaining ethical standards in trading activities[73]. Future Outlook - The management provided guidance for the next fiscal year, projecting a revenue increase of approximately 15%[172]. - Investment in research and development is expected to increase by 20% to support innovation[172]. - The overall strategy includes diversifying product offerings to meet changing consumer demands[172].

Town Health International Medical Group Limited 赓健國際醫療集團有限公司 (於開曼群島註冊成立及於百慕邊存續之有限公司) (股份代號 : 3886) 目錄 目錄 | --- | --- | |------------------------------|-------| | | 頁次 | | | 2 | | 公司資料 財務摘要 | 4 | | 管理層討論及分析 | 5 | | 權益披露 | 25 | | 企業管治 | 27 | | | | | 獨立核數師審閱報告 | 29 | | 簡明綜合損益及其他全面收益表 | 31 | | 簡明綜合財務狀況表 | 33 | | 簡明綜合權益變動表 | 35 | | 簡明綜合現金流量表 | 37 | | 簡明綜合財務報表附註 | 38 | | | 65 | 詞彙表 康健國際醫療集團有限公司 二零二一年中期報告 1 公司資料 | --- | --- | |------------------------------------|--------------------------------| | | | | 公司資料 | | ...

b Town Health International Medical Group Limited 康健國際醫療集團有限公司 (於開曼群島註冊成立及於百慕達存續之有限公司) (股份代號 : 3886) 康健國際醫療集團有限公司 2020 年報 | --- | --- | |-------|----------------------------| | | | | 目錄 | | | 2 | 公司資料 | | 4 | 行政總裁報告 | | 7 | 管理層討論與分析 | | 26 | 董事及高級管理人員個人資料 | | 29 | 環境、社會及管治報告 | | 51 | 董事會報告 | | 64 | 企業管治報告 | | 77 | 獨立核數師報告 | | 86 | 綜合損益及其他全面收益表 | | 87 | 綜合財務狀況表 | | 89 | 綜合權益變動表 | | 91 | 綜合現金流量表 | | 93 | 綜合財務報表附註 | | 213 | 主要物業資料 | | 214 | 財務摘要 | | 215 | 詞彙表 | 1 康健國際醫療集團有限公司 2020 年報 | --- | --- | |----------- ...

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability) (Stock Code : 3886) Town Health International Medical Group Limited 康健國際醫療集團有限公司 （於開曼群島註冊成立及於百慕達存續之有限公司） （股份代號 : 3886） 2020中期報告 Interim Report 2020 目錄 目錄 | --- | --- | |------------------------------|-------| | | 頁次 | | 公司資料 | 2 | | 財務摘要 | 4 | | 管理層討論與分析 | 5 | | 權益披露 | 24 | | 企業管治 | 26 | | 獨立核數師審閱報告 | 28 | | 簡明綜合損益及其他全面收益表 | 30 | | 簡明綜合財務狀況表 | 32 | | 簡明綜合權益變動表 | 34 | | 簡明綜合現金流量表 | 36 | | 簡明綜合財務報表附註 | 37 | | 詞彙表 | 64 | 1 康健國 ...

@ Town Health International Medical Group Limited 康健國際醫療集團有限公司 (於開曼群島註冊成立及於百慕達存續之有限公司) (股份代號 : 3886) 0 (Q) 0 Vice Page T F - 1000 rs. e i 0110 milli mil mill TIME TML Finin 蒲而 THE TSTON → | A Dr Vio & Partners l Dan and momm THE POLICITIE T 10 0 OHTH THE OFFICE OF THE indom 10000 TIME T FIFIE 11017710 0 ● 康健國際醫療集團有限公司 2019 年報 | --- | --- | |-------|----------------------------| | | | | | | | 目錄 | | | 2 | 公司資料 | | 5 | 行政總裁報告 | | 9 | 管理層討論與分析 | | 23 | 董事及高級管理人員個人資料 | | 28 | 環境、社會及管治報告 | | 49 | 董事會報告 | | 63 | ...

L Town Health International Medical Group Limited 康健國際醫療集團有限公司 (於関曼群島註冊成立及於百慕建得續之有限公司) (股份代號 : 3886) OWN FILALTE 网 器科生与用品 Q (0) C SEAR GENER UR ■ 图 中期報告 2 目錄 目錄 頁次 公司資料 2 財務摘要 4 管理層討論與分析 5 權益披露 21 企業管治 25 獨立核數師審閱報告 28 簡明綜合損益及其他全面收益表 30 簡明綜合財務狀況表 32 簡明綜合權益變動表 34 簡明綜合現金流量表 36 簡明綜合財務報表附註 37 詞彙表 66 1 康健國際醫療集團有限公司 二零一九年中期報告 公司資料 公司資料 | --- | --- | |----------------------------------------------|-------------------------------------------| | 董事會 | 薪酬委員會 | | 執行董事 | 何國華先生， 榮譽勳章 （主席） | | 蔡加怡小姐 （主席） | 于學忠先生 | | 許家驊醫生 ...

Financial Performance - The group's revenue for the year increased by approximately 1.17% to about HKD 1,121,736,000, with a profit of about HKD 85,509,000 compared to a loss of HKD 75,679,000 the previous year[13]. - The gross profit margin for the year was approximately 33.21%, up from 32.65% in the previous year[13]. - The net profit from continuing operations was HKD 85,509, compared to a loss of HKD 97,360 in the previous year, indicating a significant turnaround[192]. - Basic earnings per share for the year was HKD 0.85, recovering from a loss of HKD 1.41 in 2017[193]. - The total comprehensive income for the year was HKD 39,882, compared to HKD 13,277 in 2017, showing a substantial increase[193]. - The company reported a pre-tax profit of HKD 115,003, a significant recovery from a loss of HKD 71,375 in the previous year[192]. Revenue Growth and Business Segments - Revenue from the third-party medical network management business experienced single-digit percentage growth, but net profit margin has declined under competitive pressure and rising rental and labor costs[6]. - The medical beauty business segment "Xue Xian Shou" has shown steady revenue growth in Hong Kong after restructuring frontline staff, while the mainland medical beauty market continues to grow at a double-digit percentage rate[7]. - The revenue from the medical beauty business "Xue Xian Shou" reached approximately HKD 289,443,000, an increase from HKD 247,482,000 in 2017, reflecting a growth of about 17%[25]. - The overall revenue of Nanshi Hospital increased by approximately 20% during the year, with the average length of patient hospitalization reduced to 10.6 days[26]. - The high-end medical examination business in Guangzhou saw a revenue increase of about 25% compared to the previous year[27]. - Revenue from the mainland medical beauty business grew nearly 20%, with minimally invasive procedures contributing the most[29]. Operational Challenges - The overall gross margin of the self-operated chain clinic business has slightly decreased due to a shortage of doctors and rising labor costs[6]. - The overall performance of the general and dental chain clinics is facing bottlenecks, while specialized clinics continue to maintain high growth rates[6]. - Nanshi Hospital's inpatient business revenue increased nearly 20% this year, but labor costs rose by approximately 22%, leading to a decline in profit margins[8]. - The group faced a temporary vaccine supply shortage affecting its health management centers due to increased demand from mainland clients for the HPV vaccine[24]. Strategic Developments - The company remains committed to developing the mainland medical market, viewing it as a new revenue and profit growth point despite current investments being in the early layout stage[6]. - The company plans to replicate the Hong Kong model in newly established health management centers in mainland China to achieve economies of scale[7]. - The group plans to establish a chain of comprehensive health management centers in key regions, with the flagship store in Jinan expected to open in mid-2019[12]. - The company is collaborating closely with China Life Group to develop chain health management centers in Hong Kong and mainland China, although these centers have not yet achieved profitability[24]. - The group aims to maintain a stable growth trajectory for the third-party medical network management business, targeting a double-digit percentage pre-tax net profit margin[6]. Investments and Financial Position - The company has invested HKD 640,000,000 in acquiring equity and/or increasing capital in Nanyang Xiangrui for the development of medical clinics in China[120]. - Approximately HKD 650,000,000 of the raised funds is intended for the acquisition, investment, and development of hospitals and medical institutions in China, and health-related businesses in Hong Kong[117]. - The company reported a fair value gain of HKD 6,208 on equity instruments, which was not present in the previous year[192]. - As of December 31, 2018, the company held cash and bank balances of approximately HKD 1,720,425,000, an increase from HKD 1,391,559,000 in 2017[39]. - The debt-to-equity ratio was 0.46% as of December 31, 2018, down from 0.49% in 2017, reflecting a commitment to minimizing debt levels[39]. Corporate Governance and Management - The company has a strong board of independent non-executive directors with diverse professional backgrounds, enhancing governance and oversight[52]. - The management team includes experienced professionals with backgrounds in finance, law, and healthcare, contributing to strategic development and operational management[46][47][48]. - The board consists of 14 members, including 5 executive directors and 6 independent non-executive directors[151]. - The company adopted a nomination policy effective from January 1, 2019, to ensure fair and transparent director nominations[152]. - The independent non-executive directors confirmed their independence as per the listing rules, ensuring governance integrity[159]. Environmental and Social Responsibility - The group identified five key areas of significance in environmental, social, and governance aspects: labor standards, customer service, customer privacy, product and service quality, and safety and hygiene of medical centers[61]. - The group has implemented measures to protect the environment, reduce carbon emissions, and establish a green workspace[66]. - The company handled medical waste according to local regulations, ensuring proper disposal to minimize public health and environmental risks[72]. - The company actively supports community service and collaborates with local charities to aid underprivileged communities and foster youth development[68]. - The total greenhouse gas emissions for the year amounted to 1,792.34 tons of CO2 equivalent, with a density of 23 tons of CO2 equivalent per million HKD in total revenue[71].